Liquid Embolic Agent Market (2025 - 2033) Size, Share & Trends Analysis Report By Product Type (Ethylene Vinyl Alcohol Copolymer, Cyanoacrylates), By Application (Arteriovenous Malformations, Hypervascular Tumors), By End Use, By Region, And Segment Forecasts

Liquid Embolic Agent Market Summary

The global liquid embolic agent market size was estimated at USD 257.9 million in 2024 and is projected to reach USD 595.0 million by 2033, growing at a CAGR of 9.89% from 2025 to 2033. The liquid embolic agent industry is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases worldwide.

As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions like aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The growing neurovascular and peripheral vascular abnormalities and diseases such as AVMs, dural arteriovenous fistulas (DAVFs), and hypervascular tumors, among others are primarily driving the market growth. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages.

Children are more likely than adults to be present with hemorrhage. While hemorrhages are typically intraparenchymal, they can also primarily occur in the subarachnoid space. In addition, according to an article published by Radiopaedia.org in November 2024, the incidence of solitary AVM is 98% and multiple AVM is 2%. Thus, growing AVM cases are a primary contributor to market growth.

Furthermore, according to an American Chemical Society report published in April 2021, brain aneurysms are abnormal dilations that primarily develop at the branch points of cerebral blood vessels. Over 60% of aneurysms are now managed using minimally invasive endovascular techniques, such as flow diversion or the permanent placement of metallic intrasaccular coils. However, these current devices have an unfavorable primary success rate in approximately 20-30% of cases, and the overall effectiveness varies significantly depending on the aneurysm’s type and location. Hence, this brings a growth opportunity for the liquid embolic agent industry during the forecast period.

Neurovascular embolization is commonly performed using liquid embolic agents to treat conditions such as AVMs, DAVFs, and hypervascular tumors. Currently, commonly used liquid embolic agents include n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) based agents, such as Onyx (Medtronic), Squid (Balt), and PHIL (Terumo), a non-biodegradable iodine-based liquid embolic agent. Additionally, TRUFILL (CERENOVUS, Johnson & Johnson) has recently been introduced. For instance, in March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS’s hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. These agents are favored for their ability to effectively occlude abnormal vascular structures, providing minimally invasive treatment options with high precision. The choice of embolic agent depends on the specific clinical scenario and lesion characteristics, with ongoing innovations aiming to improve safety, handling, and long-term efficacy in neurointerventional procedures.

Recent Product Approvals/Launches with Applications in Neurovascular and Peripheral Vascular Interventions

Source: U.S. FDA, Company Website

Recent product launches, approvals, and commercial availability indicate that the market is poised for significant growth potential during the forecast period, mainly n-BCA, EVOH, and recently emerged blended liquid embolic agents with expanding applications is expected to fuel the market growth further. For instance, in February 2025, Guerbet announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Device designation to LIPIOJOINT, an innovative transient liquid embolic agent developed to help relieve pain and improve mobility in patients suffering from knee osteoarthritis (KOA) 

In addition, the growing reimbursement scenario is further expected to boost market growth. Sirtex launched a reimbursement guide for its LAVA Liquid Embolic System (CPT code: CPT 37244) for hospital outpatient, physician services, and office-based lab. Below is reimbursement information for the LAVA Liquid Embolic System:

HOSPITAL OUTPATIENT (OPPS)

PHYSICIAN (MFPS) SERVICES

OFFICE-BASED LAB (OBL)

Source: Sirtex

Key Opinion Leaders

Source: Grand View Research Analysis

Market Concentration & Characteristics

The market growth stage is high, and the pace is accelerating. The liquid embolic agent industry is characterized by a high degree of growth owing to growing cases of neurovascular and peripheral vascular conditions and the increasing focus of manufacturers on expanding the manufacturing of liquid embolic agent.

Technological innovations, such as the development of more biocompatible and radiopaque embolic materials, have enhanced procedural safety and efficacy, further fueling market growth. For instance, the materials used in Sirtex’s LAVA Liquid embolic agents are non-toxic and biocompatible.

Regulations significantly influence the liquid embolic agent industry by ensuring safety, efficacy, and quality standards. Stringent approval processes can delay product launches and increase costs, while relaxed regulations may pose safety risks. Overall, regulatory frameworks shape market dynamics, fostering innovation while emphasizing patient safety and compliance requirements.

The liquid embolic agent industry faces competition from various product substitutes such as coil embolization devices, vascular plugs, and solid embolic materials like particles and sclerosants. These alternatives are chosen based on specific clinical needs, offering benefits like ease of use, cost-effectiveness, or suitability for certain procedures, influencing market dynamics and product selection.

Manufacturers and companies operating in the industry are focusing on expanding their presence in numerous countries by gaining approvals from regulatory authorities. For instance, in June 2025, Balt announced the acquisition of its Canadian distributor, Yocan Medical Systems Ltd., which has been operating as Balt Canada Ltd. since June 2, 2025. This direct presence signifies a new milestone in Balt’s development in Canada and demonstrates its commitment to global growth and expansion.

Product Type Insights

The ethylene vinyl alcohol copolymer (EVOH) segment accounted for the largest market revenue share in 2024. EVOH (ethylene-vinyl alcohol) liquid embolic agents have emerged as the dominant technology in the liquid embolic agent industry, primarily due to their unique properties, proven effectiveness, and versatility in various medical procedures. One of the primary reasons for EVOH agents' dominance is their excellent biocompatibility and safety profile. These agents are designed to be non-adhesive, reducing the risk of catheter sticking and facilitating controlled and precise delivery. Their non-adhesive nature allows for longer and more complex procedures, giving physicians better control over embolization and minimizing complications such as unintended embolization or vessel rupture. This safety advantage makes EVOH agents particularly preferred in treating complex vascular conditions, including arteriovenous malformations (AVMs) and hypervascular tumors.The most commonly used and widely available EVOH for embolization of cerebral vascular malformations is Onyx (Medtronic), among which the most common formulation used in Onyx 18.

Overview of EVOH Copolymers

Source: NIH, Company Website

The cyanoacrylates segment is anticipated to grow at the fastest CAGR during the forecast period, due to its superior adhesive properties, rapid polymerization, and excellent biocompatibility. These characteristics make cyanoacrylates highly effective for embolization procedures, especially in treating vascular malformations, tumors, and hemorrhages.

In March 2022, Histoacryl received approval as a vascular embolization material under Japan’s Pharmaceutical Affairs Law. This approval permits its use in transcatheter embolization procedures across systemic organs, including cerebrospinal and head and neck vessels. In neurology, NBCA (N-Butyl Cyanoacrylate) is indicated for a broad spectrum of conditions, such as brain and spinal arteriovenous malformations (AVMs), dural arteriovenous fistulas (dAVFs), tumors of the head, neck, and brain, as well as hemorrhagic lesions.

According to a research article published in the Journal of Neurovascular Therapy, Histoacryl (B. Braun SE) is currently the most widely used commercially available N-BCA in endovascular therapy. However, prior to Histoacryl, TruFill and Glubran2 were available on the market. Furthermore, low cost with high success rates of n-BCA is expected to contribute to market growth over the forecast period.

Application Insights

The arteriovenous malformations (AVM) segment led the market with the largest revenue share of 46.69% in 2024. The increasing prevalence of AVMs, driven by improved diagnostic imaging and greater awareness, has led to a higher demand for targeted embolization solutions. In addition, the development of innovative, biocompatible, and highly controllable embolic agents has enhanced the safety and efficacy of AVM treatments, further fueling market growth. The expanding adoption of minimally invasive endovascular procedures for AVMs, coupled with technological advancements in embolic materials that enable better occlusion and reduced complication rates, solidifies AVMs as the leading segment in the liquid embolic agent industry in 2024.

The peripheral vasculature hemorrhage segment is expected to register at the fastest CAGR during the forecast period, owing to the growing development of more specialized and effective liquid embolic agents tailored for peripheral vessels enhances treatment outcomes for hemorrhagic conditions. For instance, in October 2023, Sirtex Medical announced the commercial launch of the LAVA Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage.

End Use Insights

The hospitals segment led the market with the largest revenue share of 47.77% in 2024. Hospitals serve as the primary setting for complex endovascular procedures involving liquid embolic agents, including treatments for AVMs, hypervascular tumors, and peripheral hemorrhages. Their equipped infrastructure and specialized personnel facilitate the use of these advanced therapies.

The ambulatory surgery centers (ASCs) segment is expected to register at the fastest CAGR during the forecast period, owing to growing preference for minimally invasive procedures, as ASCs specialize in minimally invasive treatments, making them ideal settings for embolization procedures that use liquid embolic agents, which are less invasive and offer quicker recovery times.  In addition, procedures performed in ASCs are generally more cost-effective compared to hospital settings. This economic advantage encourages healthcare providers and patients to opt for outpatient embolization treatments.

Regional Insights

North America dominated the market with the largest revenue share of 38.27% in 2024. The liquid embolic agent market in North America is experiencing significant growth driven by technological advancements, increasing prevalence of vascular disorders, and a rising preference for minimally invasive procedures. The region's well-established healthcare infrastructure, coupled with high healthcare expenditure, supports the adoption of advanced endovascular treatments. The increasing incidence of conditions such as aneurysms, arteriovenous malformations (AVMs), and hypervascular tumors has led to a higher demand for effective embolization solutions, fueling market expansion. For instance, according to Barrow Neurological Institute, approximately 300,000 Americans are affected by AVMs of the brain and spinal cord (neurological AVMs), but only around 12 percent of those affected experience symptoms.

U.S. Liquid Embolic Agent Market Trends

The liquid embolic agent market in the U.S. is anticipated to witness at a significant CAGR during the forecast period, driven by technological advancements, increasing prevalence of vascular disorders, and a rising preference for minimally invasive procedures. Liquid embolic agents are widely used in the treatment of various conditions such as arteriovenous malformations (AVMs), hypervascular tumors, peripheral hemorrhages, and other vascular anomalies. The growing incidence of stroke, cancer, and traumatic injuries has increased demand for effective embolization therapies in the country. Some of the key players operating in the U.S. and having U.S. FDA-approved products include Medtronic, CERENOVUS (Johnson & Johnson), Boston Scientific Corporation, and Terumo. Furthermore, the adoption of advanced embolic materials, including cyanoacrylate-based, non-adhesive, and ethylene vinyl alcohol copolymer agents, has improved procedural outcomes and safety profiles, fueling market expansion. The trend toward outpatient procedures is also contributing to market growth, with ambulatory surgical centers increasingly adopting embolization techniques due to their cost-effectiveness and patient convenience.

Asia Pacific Liquid Embolic Agent Market Trends

Asia Pacific is projected to be the fastest-growing region during the forecast period, with a CAGR of 11.07%. Growth is propelled by the rising prevalence of neurovascular disorders-such as aneurysms and AVMs-in aging populations across China, India, and Japan. Rapid healthcare infrastructure investment, expanding hospital networks, and growing awareness of minimally invasive endovascular procedures are boosting the adoption of liquid embolic systems. Moreover, local manufacturing and favorable pricing improve access in emerging economies, while regulatory frameworks are enabling faster product approvals and market entry.

The China liquid embolic agent market is expected to grow at a substantial CAGR during the forecast period, due to increasing healthcare investments, a rising prevalence of arteriovenous malformations and tumors, by occlude abnormal blood vessels. China's expanding healthcare infrastructure, rising prevalence of vascular diseases, and growing adoption of sophisticated treatment options are key factors fueling market expansion.

The liquid embolic agent market in India is propelled by several factors. The rising prevalence of cerebrovascular diseases, vascular malformations, and tumors has boosted the adoption of embolization techniques. Further, growing clinical studies using liquid embolic agents are expected to boost market growth during the forecast period. For instance, in December 2024, NeuroSafe Medical Co., Ltd. announced that the first hyper-vascular tumor case was performed in India using the Lava Liquid Embolic System.

Europe Liquid Embolic Agent Market Trends

The liquid embolic agent market in Europe is anticipated to grow at a significant CAGR during the forecast period, driven by the rising incidence of cerebrovascular conditions-particularly brain aneurysms and arteriovenous malformations-alongside the expanding adoption of minimally invasive neurointerventional procedures across hospital networks. Within Europe, growth is notably strong in Germany, where intensive clinical trials and research programs support new use‑cases and broadened device approvals. Key market drivers include technological advances in delivery systems and polymer formulations (such as EVOH‑based and cyanoacrylate agents), plus increasing availability of trained interventional radiologists following EU‑supported training initiatives. Hospital end‑users account for the largest share of usage due to high procedure volumes.

The UK liquid embolic agent market is experiencing strong growth, driven by the increasing prevalence of vascular disorders, advancements in minimally invasive endovascular procedures, and a rising emphasis on outpatient treatment options. The growing incidence of conditions such as brain arteriovenous malformations, tumors, and hemorrhages has heightened demand for effective embolization therapies, fueling the adoption of liquid embolic agents like cyanoacrylate glues and EVOH. Technological innovations, including improved delivery systems and bio-compatible materials, have enhanced procedural safety and efficacy, encouraging wider clinical use. The UK’s healthcare system, supported by favorable reimbursement policies and regulatory approvals, fosters an environment conducive to the adoption of advanced embolic solutions. In addition, the shift towards outpatient procedures in ambulatory surgical centers aligns with the government’s focus on reducing healthcare costs while maintaining high-quality care.

The liquid embolic agent market in France is witnessing significant growth driven by advancements in minimally invasive procedures and increasing demand for effective vascular intervention therapies. Liquid embolic agents are used to occlude abnormal blood vessels, treat AVMs, and manage bleeding disorders, making them essential in neurovascular, oncological, and peripheral vascular treatments. France's healthcare system's emphasis on innovative medical technologies and minimally invasive techniques has contributed to the rising adoption of liquid embolic agents. Furthermore, the increasing prevalence of cerebrovascular diseases, such as stroke and aneurysms, has fueled demand for embolization procedures. The market is also supported by technological advancements, including improved imaging guidance and the development of biocompatible, biodegradable embolic materials that enhance safety and efficacy.

The Germany liquid embolic agent market is witnessing steady growth. Growth is driven by a rising burden of neurovascular conditions like AVMs and aneurysms in Germany’s aging population, boosting demand for minimally invasive therapies. Additionally, advances in embolic agents (e.g., EVOH formulations) and improved delivery technologies enhance safety and precision. Germany’s strong clinical research infrastructure and physician training programs also accelerate the adoption and commercialization of new systems.

Latin America Liquid Embolic Agent Market Trends

The liquid embolic agent market in Latin America is expected to grow at the fastest CAGR over the forecast period, driven by the rising incidence of neurovascular disorders and hypervascular tumors, especially in Brazil and Mexico. While embolic coils currently dominate the segment, liquid agents are gaining momentum, particularly in AVM and tumor interventions. Major country-level growth in Brazil, Mexico, Argentina, and Colombia reflects improving access and regulatory progress.

Middle East and Africa Liquid Embolic Agent Market Trends

The liquid embolic agent market in the Middle East and Africa is expected to witness at a significant CAGR during the forecast period, driven by increasing applications in neurovascular procedures, oncology, and trauma care, alongside investments in interventional radiology infrastructure. However, challenges such as high costs, lack of reimbursement, and shortage of skilled professionals may impact broader adoption across the region. In the Middle East and Africa, South Africa leads in adoption, utilizing agents like Onyx and Lipiodol for treating arteriovenous malformations and hypervascular tumors.

Key Liquid Embolic Agent Company Insights

Medtronic, Johnson & Johnson, B. Braun SE, Balt, Boston Scientific Corporation, Terumo, Meril, Balt, Sirtex (BlackSwan Vascular, Inc.),and INVAMED are some of the major players in the liquid embolic agent industry. Companies in the industry are introducing innovative products and expanding their manufacturing capacities to strengthen their market presence. In addition, manufacturers are investing significantly in development of liquid embolic agent to enhance global distribution and meet growing international demand.

Recent Developments

• In July 2025, Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic (PELE) clinical trial. This study aims to assess the safety and efficacy of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhages in the peripheral vasculature.

• In June 2025, Balt announced the acquisition of its Canadian distributor, Yocan Medical Systems Ltd., which has been operating as Balt Canada Ltd. since June 2, 2025. This direct presence signifies a new milestone in Balt’s development in Canada and demonstrates its commitment to global growth and expansion.

• In February 2025, Guerbet announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Device designation to LIPIOJOINT, an innovative transient liquid embolic agent developed to help relieve pain and improve mobility in patients suffering from knee osteoarthritis (KOA).

• In March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS’s hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. Designed to streamline procedure preparation, the set simplifies the process by consolidating essential components into a single sterilized package.

• In July 2024, Arsenal Medical announced that the EMBO-01 clinical trial, an open-label, multicenter, prospective study of NeoCast, successfully met its primary feasibility and safety goals. The study demonstrated that NeoCast achieved predictable and well-controlled vascular occlusion, showcasing its effectiveness as a shear-responsive liquid embolic material engineered for deep distal penetration into the microvasculature.

• In October 2023, Sirtex Medical announced the commercial launch of the LAVA Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage.

• In April 2023, Sirtex’s (BlackSwan Vascular) Lava Liquid Embolic System received U.S. FDA approval to market this product.

• In May 2021, China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” announced that the Group has recently entered into an equity transfer agreement (“Transfer Agreement”) with Jiangsu Shenming Medical Technology Co., Ltd. (“Shenming Medical”). Under the agreement, the Group will invest USD 3.15 million to acquire a 100% equity interest in Shenming Medical once the specified conditions are met. This acquisition will grant the Group all rights related to the development and commercialization of Shenming Medical’s thermosensitive embolic agents for liver cancer treatment, as well as the subsequent development of gel products created by Shenming Medical. Notably, Shenming Medical’s thermosensitive embolic agent has been recognized as an innovative medical device by the National Medical Products Administration of China (“NMPA”).

• In April 2021, Sirtex Medical and BlackSwan Vascular, Inc. announced the enrollment of the first patient in the pivotal LAVA Study. The LAVA Study, short for Liquid Embolization of Arterial Hemorrhages in Peripheral Vasculature, is a prospective, multicenter, single-arm trial involving 113 participants across 20 investigational sites in the U.S. The first patient was enrolled at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, where a clinical team successfully treated a patient with a bleeding hypervascular liver tumor using the Lava Liquid Embolic System (LES).

Liquid Embolic Agent Market Report Scope

Global Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liquid embolic agent market report based on product type, application, end use, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Ethylene Vinyl Alcohol Copolymer (EVOH)

  • Cyanoacrylates

    • N-BCA (n-Butyl Cyanoacrylate)

    • N-HCA (n-Hexyl Cyanoacrylate)

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Arteriovenous Malformations (AVM)

  • Hypervascular Tumors

  • Peripheral Vasculature Hemorrhage

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Specialty Clinics

  • Ambulatory Surgical Centers (ASCs)

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait